Talk:Array BioPharma
Jump to navigation
Jump to search
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
Notability
PharmEditor (talk) 00:48, 4 January 2016 (UTC) This company is notable. It is in the NASDAQ biotechnology index. Please remove
- Notability on Wikipedia is defined for companies at WP:CORP - and being listed a NASDAQ index is not in itself a means to demonstrate notability - although it would suggest adequate third-party sources may exist which would then establish notability.
- Per WP:CORP: "A company, corporation, organization, school, team, religion, group, product, or service is notable if it has been the subject of significant coverage in secondary sources. Such sources must be reliable, and independent of the subject. A single independent source is almost never sufficient for demonstrating the notability of an organization."
- To establish notability, please demonstrate that multiple third-party source discuss the company (ie: not just listing them, nor simply mentioning them in passing, but provide depth of coverage). Note that press-releases reprinted by third-party sources are also not sufficient to demonstrate notability. --- Barek (talk • contribs) - 00:56, 4 January 2016 (UTC)
Needs independent sourcing
The following has almost no independent sourcing and was moved here per WP:PRESERVE. Per WP:BURDEN please do not restore without finding independent, reliable sources, checking the content against them, and citing them, and ensuring that this content has appropriate WP:WEIGHT in the article overall.
- Pipeline
As of 2016, Array BioPharma has a number of compounds in clinical development.[1]
| Drug Name | Stage in Clinical Trials | Development Partner | Indication | Target |
|---|---|---|---|---|
| Binimetinib (MEK162) | Phase 3 | None | Cancer | MEK |
| Encorafenib (LGX818) | Phase 3 | Pierre Fabre | Cancer[2][3] | BRAF |
| Selumetinib | Phase 3 | AstraZeneca | Cancer | MEK |
| Danoprevir | Phase 3 | Roche | Hepatitis C | NS3 |
| Filanesib (ARRY-520) | Phase 2 | None | Multiple myeloma[4] | KSP |
| ARRY-797 | Phase 2 | None | LMNA-related DCM | p38 |
| ARRY-502 | Phase 2 | None | Asthma | CRTh2 |
| Ipatasertib (GDC-0068) | Phase 2 | Genentech | Cancer | AKT |
| Motolimod (VTX-2337) | Phase 2 | VentiRX, Celgene | Cancer | TLR e.g. TLR8[5] |
| Varlitinib (ASLAN001) | Phase 2 | ASLAN | Cancer | Pan-HER |
| LY2606368 | Phase 2 | Eli Lilly | Cancer | CHEK1 |
| LOXO-101 | Phase 2 | Loxo Oncology | Cancer | Pan-TRK |
| ONT-380 | Phase 2 | Oncothyreon | Breast cancer | HER2/neu |
| ARRY-382 | Phase 1 | None | Cancer | CSF1R |
| ARRY-614 | Phase 1 | None | Myelodysplastic syndrome (MDS) | p38/Tie2 |
| GDC-0575 | Phase 1 | Genentech | Cancer | CHEK1 |
| GDC-0994 | Phase 1 | Genentech | Cancer | ERK |
References
- ^ "Product Pipeline".
- ^ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
- ^ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
- ^ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.
- ^ Immune Stimulant No Help When Added to Chemotherapy for Recurrent Ovarian Cancer. March 2017